Su et al. demonstrated that TGF-β1 treatment promotes EMT and invasion in gastric cancer cells, accompanied by elevated expression of Rac1 and β-catenin, effects that can be mitigated by diallyl disulfide [83]. This evidence concerns the gene RAC1 and gastric cancer.